Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

Who Took Part

The abstract describes 25 men taking part.

By PubMed's age tags, the people studied were middle-aged adults, men only.

Key outcomes were compared with previous results in men with normal weight or obesity.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The men were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of Oxytocin, giving a reference point.

Each person switched between Oxytocin and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Oxytocin, Glucose Tolerance Test, Blood Glucose, Insulin Resistance, Insulin and Glucose Intolerance.

The authors tagged it with the keywords glucose metabolism, oral glucose tolerance test and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in 25 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Oxytocin compound page, all human trials.